tirzepatide isoelectric point Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tablets Frontiers | Machine learning-guided optimization

[13] It remains an investigational medicinal product (IMP), meaning it is not licensed for routine clinical use in any country and is currently only accessible to patients enrolled in authorised clinical trials

Second, the gap between tirzepatide and retatrutide (approximately 6 percentage points) is smaller than the gap between semaglutide and tirzepatide (approximately 7-8 percentage points), which means the incremental benefit of adding glucagon agonism is real but not proportionally larger than the benefit of adding GIP

So its possible that side effects, including insomnia, will improve as your body gets used to the drug